List view / Grid view


Developing antibody therapeutics

10 June 2015 | By

Monoclonal antibodies have come of age as therapeutics; there are now more than 30 antibodies on the market and over 200 in clinical trials. The attractions of therapeutic antibodies lie not only in their potential to make potent drugs but also their relative low risk in comparison to small molecule…

Drug Target Review – Issue #1 2015

9 April 2015 | By J.R. Costa, J. Heintze, R. Ketteler, K. Papenfuss, C. Richards, S. Nahnsen, N. Graffman, P. Matz, W.Wruck, J. Adjaye, C. Williams, W. Fecke.

In this issue: Next-Generation Sequencing, Drug Targets, High Throughput Screening, Phenotypic Screening, Stem cells, Label-Free technologies and Assays...

NGS In-Depth Focus 2015

9 April 2015 | By Caroline Richards, Editor, Drug Target Review

In this NGS In-Depth Focus; How next-generation sequencing came to be, plus a brief history & Data management for large-scale NGS-based research projects...

Drug Targets In-Depth Focus 2015

9 April 2015 | By J.R.Costa, J.Heintze, R.Ketteler, S. Gul, Dr. T.Duensing, K.Papenfuss.

In this Drug Targets In-Depth Focus, we delve into the role of a key complex required for autophagosome maturation, the ATG4-ATG8 conjugation system, and we provide insight on some up-and-coming immune checkpoint inhibitors that are currently in clinical and preclinical development...

Label-free technologies for monitoring drug interactions

9 April 2015 | By ,

In his fascinating overview of label-free analysis, Dr. Masson introduces the four main label-free methods: physical, electrochemical, mass-based and optical techniques, before providing the reader with in-depth insight into the most common label-free technique within the pharmaceutical industry: surface plasmon resonance (SPR)...